Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022

Rhea-AI Summary

Immunovant, a clinical-stage biopharmaceutical company focused on autoimmune diseases, will host a webcast on September 7, 2022 at 8:00 AM ET to announce two new indications for batoclimab. The event will feature remarks from company management and external key opinion leaders, followed by a live Q&A session. Interested participants can register for the webcast here. An archived recording will be available on the company's website afterward.

NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, will host a webcast for the investment community to announce two new indications for batoclimab on Wednesday, September 7, 2022 at 8:00 AM ET.

The event will feature prepared remarks by company management and external key opinion leaders. A live question-and-answer session with company management will follow the formal presentations. To access the webcast, please register here.

An archived recording of the webcast will be available on Immunovant’s website for a limited time following its conclusion.

About Immunovant, Inc. 

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. The Company’s investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com. 

Contact:
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com

FAQ

What is the date and time for Immunovant's webcast about batoclimab?

The webcast is scheduled for September 7, 2022, at 8:00 AM ET.

What will be announced during the Immunovant webcast?

Two new indications for the investigational drug batoclimab will be announced.

Will there be an opportunity for questions during the Immunovant webcast?

Yes, there will be a live question-and-answer session following the presentations.

How can I access the Immunovant webcast?

You can register for the webcast by following the link provided in the press release.

Where can I find a recording of the Immunovant webcast?

An archived recording will be available on Immunovant's website for a limited time after the event.